Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Diagnostic Value of Volume-Based Fluorine-18-Fluorodeoxyglucose PET/CT Parameters for Characterizing Thyroid Incidentaloma

  • Shi, Huazheng (Shanghai Universal Medical Imaging Diagnostic Center) ;
  • Yuan, Zuguo (Department of Chemoradiotherapy, Yinzhou People's Hospital) ;
  • Yuan, Zheng (Shanghai Universal Medical Imaging Diagnostic Center) ;
  • Yang, Chunshan (Shanghai Universal Medical Imaging Diagnostic Center) ;
  • Zhang, Jian (Shanghai Universal Medical Imaging Diagnostic Center) ;
  • Shou, Yi (Shanghai Universal Medical Imaging Diagnostic Center) ;
  • Zhang, Wenrui (Shanghai Universal Medical Imaging Diagnostic Center) ;
  • Ping, Zhaofu (Shanghai Universal Medical Imaging Diagnostic Center) ;
  • Gao, Xin (Shanghai Universal Medical Imaging Diagnostic Center) ;
  • Liu, Shiyuan (Department of Radiology, affiliated Changzheng Hospital, The Second Military Medical University)
  • Received : 2017.01.24
  • Accepted : 2017.08.20
  • Published : 2018.04.01
⟨ Previous Next ⟩

Abstract

Objective: To assess clinical value of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) for differentiation of malignant from benign focal thyroid incidentaloma. Materials and Methods: This retrospective study included 99 patients with focal thyroid incidentaloma of 5216 non-thyroid cancer patients that had undergone PET/CT. PET/CT semi-quantitative parameters, volume-based functional parameters, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of thyroid incidentaloma were assessed. Receiver-operating characteristic (ROC) analysis was conducted and areas under the curve (AUC) were compared by Hanley and McNeil test to evaluate usefulness of maximum standardized uptake value (SUVmax), MTV and TLG, as markers for differentiating malignant from benign thyroid incidentalomas. Results: Of 99 thyroid incidentalomas, 64 (64.6%) were malignant and 35 (35.4%) were benign. Malignant thyroid incidentalomas were larger (1.8 cm vs. 1.3 cm, p = 0.006), and had higher SUVmax (11.3 vs. 4.8, p < 0.001), MTV (all p < 0.001) and TLG (all p < 0.001) than benign. TLG 4.0 had the highest performance for differentiation of malignant from benign thyroid incidentaloma in all semi-quantitative parameters with AUC 0.895 by ROC curve analysis. AUC (TLG 4.0) was significantly larger than AUC (SUVmean), AUC (MTV 2.5), AUC (MTV 3.0), AUC (MTV 3.5), AUC (TLG 2.5), and AUC (TLG 3.0), respectively (all, p < 0.05). There was no statistical difference between AUC (TLG 4.0) and AUC (SUVmax) (p > 0.05). A threshold TLG 4.0 of 2.475 had 81.3% sensitivity and 94.3% specificity for identifying malignant thyroid incidentalomas. Conclusion: Volume-based PET/CT parameters could potentially have clinical value in differential diagnosis of thyroid incidentaloma along with SUVmax.

Keywords

Acknowledgement

Supported by : Shanghai Municipal of Health and Family Planning Commission

References

  1. Burguera B, Gharib H. Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am 2000;29:187-203 https://doi.org/10.1016/S0889-8529(05)70123-7
  2. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009;70:382-392 https://doi.org/10.1016/j.ejrad.2009.03.051
  3. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001;2:157-164 https://doi.org/10.1016/S1470-2045(00)00257-6
  4. Chen YK, Ding HJ, Chen KT, Chen YL, Liao AC, Shen YY, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 2005;25:1421-1426
  5. Pagano L, Samà MT, Morani F, Prodam F, Rudoni M, Boldorini R, et al. Thyroid incidentaloma identified by $^{18}F$-fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT): clinical and pathological relevance. Clin Endocrinol (Oxf) 2011;75:528-534 https://doi.org/10.1111/j.1365-2265.2011.04107.x
  6. Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 2007;48:896-901 https://doi.org/10.2967/jnumed.106.039024
  7. Liu Y. Clinical significance of thyroid uptake on F18- fluorodeoxyglucose positron emission tomography. Ann Nucl Med 2009;23:17-23 https://doi.org/10.1007/s12149-008-0198-0
  8. Are C, Hsu JF, Schoder H, Shah JP, Larson SM, Shaha AR. FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol 2007;14:239-247
  9. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 2005;115:1074-1078 https://doi.org/10.1097/01.MLG.0000163098.01398.79
  10. Kim BH, Na MA, Kim IJ, Kim SJ, Kim YK. Risk stratification and prediction of cancer of focal thyroid fluorodeoxyglucose uptake during cancer evaluation. Ann Nucl Med 2010;24:721-728 https://doi.org/10.1007/s12149-010-0414-6
  11. Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100-4104 https://doi.org/10.1210/jc.2003-030465
  12. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007;28:373-381 https://doi.org/10.1097/MNM.0b013e3280964eae
  13. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med 2012;53:709-715 https://doi.org/10.2967/jnumed.111.099531
  14. I HS, Kim SJ, Kim IJ, Kim K. Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer. Clin Nucl Med 2012;37:442-446 https://doi.org/10.1097/RLU.0b013e318238f703
  15. Kim BH, Kim SJ, Kim H, Jeon YK, Kim SS, Kim IJ, et al. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma. Nucl Med Commun 2013;34:868-876
  16. Kim SJ, Chang S. Predictive value of intratumoral heterogeneity of F-18 FDG uptake for characterization of thyroid nodules according to Bethesda categories of fine needle aspiration biopsy results. Endocrine 2015;50:681-688 https://doi.org/10.1007/s12020-015-0620-z
  17. Nam SY, Roh JL, Kim JS, Lee JH, Choi SH, Kim SY. Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 2007;67:135-139 https://doi.org/10.1111/j.1365-2265.2007.02850.x
  18. Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001;130:941-946 https://doi.org/10.1067/msy.2001.118265
  19. Makis W, Ciarallo A. Thyroid incidentalomas on 18F-FDG PET/ CT: clinical significance and controversies. Mol Imaging Radionucl Ther 2017;26:93-100 https://doi.org/10.4274/mirt.94695
  20. Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 2006;47:609-615
  21. Ho TY, Liou MJ, Lin KJ, Yen TC. Prevalence and significance of thyroid uptake detected by $^{18}F-FDG$ PET. Endocrine 2011;40:297-302 https://doi.org/10.1007/s12020-011-9470-5
  22. Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab 2012;97:3866-3875 https://doi.org/10.1210/jc.2012-2390
  23. Kim H, Kim SJ, Kim IJ, Kim K. Thyroid incidentalomas on FDG PET/CT in patients with non-thyroid cancer - a large retrospective monocentric study. Onkologie 2013;36:260-264
  24. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27:861-866 https://doi.org/10.1007/s002590000258
  25. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging 2013;40:290-301 https://doi.org/10.1007/s00259-012-2280-z
  26. Salvatori M, Melis L, Castaldi P, Maussier ML, Rufini V, Perotti G, et al. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography. Biomed Pharmacother 2007;61:488-493 https://doi.org/10.1016/j.biopha.2007.05.001
  27. Kim D, Hwang SH, Cha J, Jo K, Lee N, Yun M. Risk stratification of thyroid incidentalomas found on PET/CT: the value of iodine content on noncontrast computed tomography. Thyroid 2015;25:1249-1254 https://doi.org/10.1089/thy.2015.0200
  28. Lee S, Park T, Park S, Pahk K, Rhee S, Cho J, et al. The clinical role of dual-time-point (18)F-FDG PET/CT in differential diagnosis of the thyroid incidentaloma. Nucl Med Mol Imaging 2014;48:121-129 https://doi.org/10.1007/s13139-013-0247-z
  29. Barrio M, Czernin J, Yeh MW, Palma Diaz MF, Gupta P, Allen- Auerbach M, et al. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an $^{18}F-FDG$ PET/CT study in more than 6000 patients. Nucl Med Commun 2016;37:1290-1296 https://doi.org/10.1097/MNM.0000000000000592

Cited by

  1. Diagnostic Value of FDG PET-CT Quantitative Parameters and Deauville-Like 5 Point-Scale in Predicting Malignancy of Focal Thyroid Incidentaloma vol.6, pp.None, 2018, https://doi.org/10.3389/fmed.2019.00024
  2. Re: Diagnostic Value of Volume-Based Fluorine-18-Fluorodeoxyglucose PET/CT Parameters for Characterizing Thyroid Incidentaloma vol.20, pp.6, 2018, https://doi.org/10.3348/kjr.2019.0102
  3. Evaluation of Malignancy Risk in 18F-FDG PET/CT Thyroid Incidentalomas vol.9, pp.3, 2018, https://doi.org/10.3390/diagnostics9030092
  4. Role of multi-modality functional imaging in differentiation between benign and malignant thyroid 18F-fluorodeoxyglucose incidentaloma vol.21, pp.11, 2018, https://doi.org/10.1007/s12094-019-02089-9
  5. Radiomics Analysis of [ 18 F]-Fluorodeoxyglucose-Avid Thyroid Incidentalomas Improves Risk Stratification and Selection for Clinical Assessment vol.31, pp.1, 2018, https://doi.org/10.1089/thy.2020.0224
  6. Prostate incidentaloma on 18F-fluorodeoxyglucose positron emission tomography: Diagnostic value of volumetric positron emission tomography parameters vol.60, pp.6, 2021, https://doi.org/10.1055/a-1525-7607
  7. Characterization of focal hypermetabolic thyroid incidentaloma: An analysis with F-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters vol.10, pp.1, 2018, https://doi.org/10.12998/wjcc.v10.i1.155